
STOK Stock Forecast & Price Target
STOK Analyst Ratings
Bulls say
Stoke Therapeutics has demonstrated a positive financial trajectory, with FY25 revenue rising significantly to $184 million from $36.6 million in FY24, primarily due to a substantial $165 million upfront payment from its collaboration with Biogen. The ongoing Phase III EMPEROR study of zorevunersen in Dravet syndrome shows promising early readouts, with various statistically significant improvements in seizure reduction, which supports a favorable outlook for further clinical progress. Additionally, the company's R&D expenditure increased to $138 million, reflecting its commitment to expanding its portfolio of antisense oligonucleotides and investing in innovative treatments, indicating a strong pipeline and potential for future growth.
Bears say
Stoke Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to reliance on key patents for market success; any failure to secure or maintain these patents could severely impact the company's valuation. Financially, Stoke recorded a net loss of $6.9 million for the year 2025, with expectations of continuing losses and no anticipated profitability for several years. Moreover, the company must seek additional capital to sustain operations, raising concerns regarding potential dilution of shareholder equity through future equity financings.
This aggregate rating is based on analysts' research of Stoke Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
STOK Analyst Forecast & Price Prediction
Start investing in STOK
Order type
Buy in
Order amount
Est. shares
0 shares